Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents

J Crohns Colitis. 2020 Dec 2;14(12):1794-1795. doi: 10.1093/ecco-jcc/jjaa187.

Authors

Thomas E Conley¹, Chris Probert², Sreedhar Subramanian¹

Affiliations

¹ Department of Gastroenterology, Liverpool University Foundation Hospitals NHS Trust, Liverpool, UK.
² Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool, UK.

No abstract available

Keywords: Covid-19; Inflammatory bowel disease; biologics.

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Biological Factors / therapeutic use*
COVID-19 / diagnosis
COVID-19 / epidemiology
COVID-19 / etiology*
COVID-19 / prevention & control
Female
Humans
Immunomodulating Agents / therapeutic use*
Inflammatory Bowel Diseases / complications
Inflammatory Bowel Diseases / drug therapy*
Inflammatory Bowel Diseases / immunology
Male
Middle Aged
Patient Acuity
Prevalence
Risk Factors
Self Report
Young Adult

Substances

Biological Factors
Immunomodulating Agents